NUVL Quote, Financials, Valuation and Earnings

Pfizer Inc. has a net margin of -- compared to Nuvalent, Inc.'s net margin of 21.32%. Nuvalent, Inc.'s return on equity of -38.24% beat Pfizer Inc.'s return on equity of 10.84%.

Nuvalent, Inc. has a consensus price target of $141.82, signalling upside risk potential of 32.72%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Nuvalent, Inc. has higher upside potential than Pfizer Inc., analysts believe Nuvalent, Inc. is more attractive than Pfizer Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Nuvalent, Inc.'s net income of -$122.4M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Nuvalent, Inc.'s net margin of --. Nuvalent, Inc.'s return on equity of -38.24% beat Palatin Technologies's return on equity of --.

Nuvalent, Inc. has a consensus price target of $141.82, signalling upside risk potential of 32.72%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Nuvalent, Inc., analysts believe Palatin Technologies is more attractive than Nuvalent, Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Nuvalent, Inc.'s net income of -$122.4M is higher than Palatin Technologies's net income of --. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Nuvalent, Inc.'s net margin of --. Nuvalent, Inc.'s return on equity of -38.24% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Nuvalent, Inc. has a consensus price target of $141.82, signalling upside risk potential of 32.72%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2797.35%. Given that Theriva Biologics, Inc. has higher upside potential than Nuvalent, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Nuvalent, Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Nuvalent, Inc.'s net income of -$122.4M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xencor, Inc. has a net margin of -- compared to Nuvalent, Inc.'s net margin of -28.7%. Nuvalent, Inc.'s return on equity of -38.24% beat Xencor, Inc.'s return on equity of -20.07%.

Nuvalent, Inc. has a consensus price target of $141.82, signalling upside risk potential of 32.72%. On the other hand Xencor, Inc. has an analysts' consensus of $28.00 which suggests that it could grow by 54.36%. Given that Xencor, Inc. has higher upside potential than Nuvalent, Inc., analysts believe Xencor, Inc. is more attractive than Nuvalent, Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xencor, Inc. has a beta of 0.960, suggesting its less volatile than the S&P 500 by 3.97%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Xencor, Inc. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Xencor, Inc. quarterly revenues of $21M. Nuvalent, Inc.'s net income of -$122.4M is lower than Xencor, Inc.'s net income of -$6M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Xencor, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 8.93x for Xencor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.